Galectin Therapeutics Inc. – NASDAQ:GALT
Galectin Therapeutics stock price today
$3.81
+2.66
+231.3%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 4 hours
Galectin Therapeutics stock price monthly change
-48.66%
month
Galectin Therapeutics stock price quarterly change
-48.66%
quarter
Galectin Therapeutics stock price yearly change
-31.14%
year
Galectin Therapeutics key metrics
Market Cap | 56.07M |
Enterprise value | 142.39M |
P/E | -3.04 |
EV/Sales | N/A |
EV/EBITDA | -2.50 |
Price/Sales | N/A |
Price/Book | -3.57 |
PEG ratio | 0.12 |
EPS | -0.67 |
Revenue | N/A |
EBITDA | -37.24M |
Income | -41.02M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGalectin Therapeutics stock price history
Galectin Therapeutics stock forecast
Galectin Therapeutics financial statements
| Jun 2023 | 0 | -9.11M | |
|---|---|---|---|
| Sep 2023 | 0 | -10.42M | |
| Dec 2023 | 80K | -9.99M | -12496.25% |
| Mar 2024 | 0 | -11.48M |
| 2025 | 36.32M | -95.65M | -263.36% |
|---|---|---|---|
| 2026 | 179.68M | -58.35M | -32.48% |
| 2027 | 385.24M | 79.40M | 20.61% |
| 2028 | 572.21M | 206.34M | 36.06% |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | 0.26% |
|---|---|
| 2020 | 0.11% |
| 2021 | 0.14% |
| 2022 | 0.14% |
| 2023 |
| Jun 2023 | 20081000 | 71.20M | 354.6% |
|---|---|---|---|
| Sep 2023 | 22163000 | 73.03M | 329.54% |
| Dec 2023 | 28200000 | 88.44M | 313.62% |
| Mar 2024 | 25890000 | 96.97M | 374.57% |
| Jun 2023 | -9.83M | 0 | 10M |
|---|---|---|---|
| Sep 2023 | -7.63M | 0 | 10.03M |
| Dec 2023 | -4.70M | 0 | 10M |
| Mar 2024 | -12.10M | 0 | 10M |
Galectin Therapeutics alternative data
| Aug 2023 | 12 |
|---|---|
| Sep 2023 | 12 |
| Oct 2023 | 12 |
| Nov 2023 | 12 |
| Dec 2023 | 12 |
| Jan 2024 | 12 |
| Feb 2024 | 12 |
| Mar 2024 | 12 |
| Apr 2024 | 12 |
| May 2024 | 28 |
| Jun 2024 | 28 |
| Jul 2024 | 14 |
Galectin Therapeutics other data
12.75%
+0.40%
of GALT is owned by hedge funds
7.46M
+137.21K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 500 | 0 |
| Apr 2024 | 4500 | 25000 |
| Jun 2024 | 2500 | 0 |
| Jul 2024 | 400 | 0 |
| Aug 2024 | 3500 | 0 |
| Oct 2024 | 11800 | 0 |
| Dec 2024 | 33469 | 109654 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | ZORDANI RICHARD A. JR. director | Common Stock | 10,000 | $0.82 | $8,160 | ||
Purchase | ELDRED KARY director | Common Stock | 13,469 | $0.82 | $11,045 | ||
Purchase | FREEMAN KEVIN D director | Common Stock | 10,000 | $0.81 | $8,130 | ||
Option | JAMIL KHURRAM officer: Chief Medical Officer | Common Stock | 40,000 | N/A | N/A | ||
Sale | JAMIL KHURRAM officer: Chief Medical Officer | Common Stock | 13,654 | $0.88 | $12,043 | ||
Option | JAMIL KHURRAM officer: Chief Medical Officer | Restricted Stock Units | 40,000 | N/A | N/A | ||
Option | LEWIS JOEL director, officer.. | Common Stock | 56,000 | N/A | N/A | ||
Sale | LEWIS JOEL director, officer.. | Common Stock | 56,000 | $0.89 | $49,616 | ||
Option | LEWIS JOEL director, officer.. | Restricted Stock Units | 56,000 | N/A | N/A | ||
Option | CALLICUTT JACK W officer: Chief Financial Officer | Common Stock | 40,000 | N/A | N/A |
| Patent |
|---|
Application Filling date: 28 Sep 2020 Issue date: 1 Apr 2021 |
Application Filling date: 3 Aug 2020 Issue date: 14 Jan 2021 |
Grant Filling date: 30 Jul 2019 Issue date: 13 Oct 2020 |
Grant Filling date: 28 Aug 2017 Issue date: 18 Aug 2020 |
Application Filling date: 30 Jul 2019 Issue date: 12 Mar 2020 |
Grant Filling date: 8 May 2018 Issue date: 24 Sep 2019 |
Grant Filling date: 22 Jan 2018 Issue date: 3 Sep 2019 |
| Quarter | Transcript |
|---|---|
| Q4 2016 28 Mar 2017 | Q4 2016 Earnings Call Transcript |
| Q4 2015 15 Mar 2016 | Q4 2015 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Pol F. Boudes (1957) Chief Medical Officer | $663,020 |
| Mr. Joel Lewis (1970) Pres, Chief Executive Officer & Director | $601,100 |
-
What's the price of Galectin Therapeutics stock today?
One share of Galectin Therapeutics stock can currently be purchased for approximately $3.81.
-
When is Galectin Therapeutics's next earnings date?
Unfortunately, Galectin Therapeutics's (GALT) next earnings date is currently unknown.
-
Does Galectin Therapeutics pay dividends?
No, Galectin Therapeutics does not pay dividends.
-
How much money does Galectin Therapeutics make?
Galectin Therapeutics has a market capitalization of 56.07M.
-
What is Galectin Therapeutics's stock symbol?
Galectin Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "GALT".
-
What is Galectin Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Galectin Therapeutics?
Shares of Galectin Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Galectin Therapeutics's key executives?
Galectin Therapeutics's management team includes the following people:
- Dr. Pol F. Boudes Chief Medical Officer(age: 68, pay: $663,020)
- Mr. Joel Lewis Pres, Chief Executive Officer & Director(age: 55, pay: $601,100)
-
How many employees does Galectin Therapeutics have?
As Jul 2024, Galectin Therapeutics employs 14 workers, which is 50% less then previous month and 17% more then previous quarter.
-
When Galectin Therapeutics went public?
Galectin Therapeutics Inc. is publicly traded company for more then 23 years since IPO on 4 Sep 2002.
-
What is Galectin Therapeutics's official website?
The official website for Galectin Therapeutics is galectintherapeutics.com.
-
Where are Galectin Therapeutics's headquarters?
Galectin Therapeutics is headquartered at 4960 Peachtree Industrial Boulevard, Norcross, GA.
-
How can i contact Galectin Therapeutics?
Galectin Therapeutics's mailing address is 4960 Peachtree Industrial Boulevard, Norcross, GA and company can be reached via phone at +678 6203186.
Galectin Therapeutics company profile:
Galectin Therapeutics Inc.
galectintherapeutics.comExchange:
NASDAQ
Full time employees:
14
Industry:
Biotechnology
Sector:
Healthcare
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
4960 Peachtree Industrial Boulevard
Norcross, GA 30071
Norcross, GA 30071
CIK: 0001133416
ISIN: US3632252025
CUSIP: 363225202
